107 (Phospho)proteomics biomarkers for sunitinib response in RCC 15 Escudier, B. et al. Renal Cell Carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30(5), 706-720, doi:https://doi.org/10.1093/annonc/mdz056 (2019). 16 Network., N. C. C. NCCN clinical practice guidelines in oncology: kidney cancer. Version 3. (2019). 17 Urology, E. A. o. Renal Cell Carcinoma Guidelines. (2019). 18 Dudani, S., Savard, M. F. & Heng, D. Y. C. An Update on Predictive Biomarkers in Metastatic Renal Cell Carcinoma. Eur Urol Focus 6, 34-36, doi:10.1016/j.euf.2019.04.004 (2020). 19 van der Mijn, J. C., Mier, J. W., Broxterman, H. J. & Verheul, H. M. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms. Drug Resist Updat 17, 77-88, doi:10.1016/j. drup.2014.10.003 (2014). 20 Stommel, J. M. et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287-290, doi:10.1126/science.1142946 (2007). 21 Fiorentino, M. et al. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. Oncotarget 8, 7328-7335, doi:10.18632/oncotarget.12551 (2017). 22 Cutillas, P. R. Role of phosphoproteomics in the development of personalized cancer therapies. Proteom Clin Appl 9, 383-395, doi:10.1002/prca.201400104 (2015). 23 Clark, D. J. et al. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell 179, 964-983 e931, doi:10.1016/j.cell.2019.10.007 (2019). 24 Beekhof, R. et al. INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases. Mol Syst Biol 15(5):e8981. doi: 10.15252/msb.20198981 (2019). 25 Labots, M. et al. Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome. Cancers (Basel) 12, doi:10.3390/cancers12020330 (2020). 26 Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203, doi:10.1016/j.cell.2007.11.025 (2007). 27 Zhang, H. et al. Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. Cell 166, 755-765, doi:10.1016/j.cell.2016.05.069 (2016). 28 Mertins, P. et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-+, doi:10.1038/nature18003 (2016). 29 Jimenez, C. R. & Verheul, H. M. Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications. Am Soc Clin Oncol Educ Book, e504-510, doi:10.14694/EdBook_AM.2014.34.e504 (2014). 30 Olsen, J. V. et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127, 635-648, doi:10.1016/j.cell.2006.09.026 (2006). 4
RkJQdWJsaXNoZXIy MTk4NDMw